Biocad

BIOCAD is a major, vertically integrated Russian biotech player with a strong focus on developing both innovative biologics and biosimilars. It operates three distinct technology platforms for monoclonal antibodies (MabNEXT), small molecules (ChemNEXT), and gene therapy (GeneNEXT), supporting a broad internal pipeline. The company manages the entire drug development cycle from discovery through clinical trials and commercial production, positioning itself as a key domestic supplier and an emerging international innovator in its therapeutic areas.

Three proprietary platforms: MabNEXT for monoclonal antibodies (with Fc-engineering), ChemNEXT for small molecules (using computational drug design), and GeneNEXT for gene therapy. Employs structural drug design and computer modeling across platforms.

In Russia/CIS, BIOCAD is a leading integrated competitor. Globally, it faces competition in biosimilars from large generics firms (e.g., Sandoz, Biocon) and in innovative biologics/gene therapy from major pharma (e.g., Roche, Amgen, Novartis) and agile biotechs. Its full-cycle integration is a key differentiator against pure-play R&D firms.